{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T12:28:15Z","timestamp":1768480095591,"version":"3.49.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T00:00:00Z","timestamp":1747612800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T00:00:00Z","timestamp":1747612800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100017346","name":"Nippon Boehringer Ingelheim","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100017346","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1007\/s13555-025-01429-8","type":"journal-article","created":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T13:51:31Z","timestamp":1747662691000},"page":"1883-1899","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Treatment Status for Generalized Pustular Psoriasis in Japanese Patients: A Retrospective Chart Review"],"prefix":"10.1007","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9526-1259","authenticated-orcid":false,"given":"Yukari","family":"Okubo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4360-6865","authenticated-orcid":false,"given":"Ryuhei","family":"Okuyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinichi","family":"Imafuku","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yayoi","family":"Tada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiichi","family":"Yamanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5207-4592","authenticated-orcid":false,"given":"Kazumitsu","family":"Sugiura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0297-6627","authenticated-orcid":false,"given":"Yukie","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahito","family":"Yasuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wataru","family":"Sakamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Morihisa","family":"Saitoh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akimichi","family":"Morita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"on behalf of the Study Investigators","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akimichi","family":"Morita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryuhei","family":"Okuyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenji","family":"Kabashima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukie","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Masuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoko","family":"Muzutani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiichi","family":"Yamanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuro","family":"Kanekura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigeto","family":"Yanagihara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiharu","family":"Tateishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukari","family":"Okubo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yayoi","family":"Tada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuya","family":"Honda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Fukushima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuki","family":"Yatsuzuka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuya","family":"Miyagi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahito","family":"Yasuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emi","family":"Yokoyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mayumi","family":"Komine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuo","family":"Kanazawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazumitsu","family":"Sugiura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Amano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daisuke","family":"Watabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koremasa","family":"Hayama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hitoshi","family":"Tsuchihashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaru","family":"Honma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masatoshi","family":"Abe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hajime","family":"Iizuka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihiko","family":"Asahina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,5,19]]},"reference":[{"issue":"11","key":"1429_CR1","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1111\/1346-8138.14523","volume":"45","author":"H Fujita","year":"2018","unstructured":"Fujita H, Terui T, Hayama K, et al. Japanese guidelines for the management and treatment of generalized pustular psoriasis: the new pathogenesis and treatment of GPP. J Dermatol. 2018;45(11):1235\u201370.","journal-title":"J Dermatol"},{"issue":"6","key":"1429_CR2","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1111\/ijd.12070","volume":"53","author":"SE Choon","year":"2014","unstructured":"Choon SE, Lai NM, Mohammad NA, Nanu NM, Tey KE, Chew SF. Clinical profile, morbidity, and outcome of adult-onset generalized pustular psoriasis: analysis of 102 cases seen in a tertiary hospital in Johor, Malaysia. Int J Dermatol. 2014;53(6):676\u201384.","journal-title":"Int J Dermatol"},{"issue":"11","key":"1429_CR3","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1111\/1346-8138.16084","volume":"48","author":"Y Okubo","year":"2021","unstructured":"Okubo Y, Kotowsky N, Gao R, Saito K, Morita A. Clinical characteristics and health-care resource utilization in patients with generalized pustular psoriasis using real-world evidence from the Japanese Medical Data Center database. J Dermatol. 2021;48(11):1675\u201387.","journal-title":"J Dermatol"},{"issue":"10","key":"1429_CR4","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1111\/1346-8138.16022","volume":"48","author":"A Morita","year":"2021","unstructured":"Morita A, Kotowsky N, Gao R, Shimizu R, Okubo Y. Patient characteristics and burden of disease in Japanese patients with generalized pustular psoriasis: results from the Medical Data Vision claims database. J Dermatol. 2021;48(10):1463\u201373.","journal-title":"J Dermatol"},{"issue":"11","key":"1429_CR5","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.1111\/jdv.14386","volume":"31","author":"AA Navarini","year":"2017","unstructured":"Navarini AA, Burden AD, Capon F, et al. European consensus statement on phenotypes of pustular psoriasis. J Eur Acad Dermatol Venereol. 2017;31(11):1792\u20139.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"9","key":"1429_CR6","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1080\/1744666X.2021.1961580","volume":"17","author":"M Komine","year":"2021","unstructured":"Komine M, Morita A. Generalized pustular psoriasis: current management status and unmet medical needs in Japan. Expert Rev Clin Immunol. 2021;17(9):1015\u201327.","journal-title":"Expert Rev Clin Immunol"},{"issue":"8","key":"1429_CR7","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1111\/exd.14824","volume":"32","author":"AD Burden","year":"2023","unstructured":"Burden AD, Okubo Y, Zheng M, et al. Efficacy of spesolimab for the treatment of generalized pustular psoriasis flares across pre-specified patient subgroups in the Effisayil\u00a01 study. Exp Dermatol. 2023;32(8):1279\u201383.","journal-title":"Exp Dermatol"},{"issue":"10412","key":"1429_CR8","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1016\/S0140-6736(23)01378-8","volume":"402","author":"A Morita","year":"2023","unstructured":"Morita A, Strober B, Burden AD, et al. Efficacy and safety of subcutaneous spesolimab for the prevention of generalised pustular psoriasis flares (Effisayil\u00a02): an international, multicentre, randomised, placebo-controlled trial. Lancet. 2023;402(10412):1541\u201351.","journal-title":"Lancet"},{"issue":"2","key":"1429_CR9","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1093\/bjd\/ljad083","volume":"189","author":"RB Warren","year":"2023","unstructured":"Warren RB, Reich A, Kaszuba A, et al. Imsidolimab, an anti-interleukin-36 receptor monoclonal antibody, for the treatment of generalized pustular psoriasis: results from the phase\u00a0II GALLOP trial. Br J Dermatol. 2023;189(2):161\u20139.","journal-title":"Br J Dermatol"},{"issue":"6","key":"1429_CR10","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1016\/j.jaad.2021.06.008","volume":"86","author":"H Miyachi","year":"2022","unstructured":"Miyachi H, Konishi T, Kumazawa R, et al. Treatments and outcomes of generalized pustular psoriasis: a cohort of 1516 patients in a nationwide inpatient database in Japan. J Am Acad Dermatol. 2022;86(6):1266\u201374.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"1429_CR11","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1111\/jdv.15287","volume":"33","author":"Y Okubo","year":"2019","unstructured":"Okubo Y, Mabuchi T, Iwatsuki K, et al. Long-term efficacy and safety of ixekizumab in Japanese patients with erythrodermic or generalized pustular psoriasis: subgroup analyses of an open-label, phase\u00a03 study (UNCOVER-J). J Eur Acad Dermatol Venereol. 2019;33(2):325\u201332.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6","key":"1429_CR12","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1007\/s13555-022-00741-x","volume":"12","author":"Y Okubo","year":"2022","unstructured":"Okubo Y, Umezawa Y, Sakurai S, Hoshii N, Nakagawa H. Efficacy and safety of certolizumab pegol in Japanese patients with generalized pustular psoriasis and erythrodermic psoriasis: 52-week results. Dermatol Ther (Heidelb). 2022;12(6):1397\u2013415.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"9","key":"1429_CR13","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1111\/1346-8138.13306","volume":"43","author":"S Imafuku","year":"2016","unstructured":"Imafuku S, Honma M, Okubo Y, et al. Efficacy and safety of secukinumab in patients with generalized pustular psoriasis: a 52-week analysis from phase\u00a0III open-label multicenter Japanese study. J Dermatol. 2016;43(9):1011\u20137.","journal-title":"J Dermatol"},{"issue":"12","key":"1429_CR14","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1111\/1346-8138.14664","volume":"45","author":"A Morita","year":"2018","unstructured":"Morita A, Yamazaki F, Matsuyama T, et al. Adalimumab treatment in Japanese patients with generalized pustular psoriasis: results of an open-label phase\u00a03 study. J Dermatol. 2018;45(12):1371\u201380.","journal-title":"J Dermatol"},{"issue":"4","key":"1429_CR15","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1111\/1346-8138.13622","volume":"44","author":"H Saeki","year":"2017","unstructured":"Saeki H, Nakagawa H, Nakajo K, et al. Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis: results from a 52-week, open-label, phase\u00a03 study (UNCOVER-J). J Dermatol. 2017;44(4):355\u201362.","journal-title":"J Dermatol"},{"issue":"5","key":"1429_CR16","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1111\/1346-8138.14294","volume":"45","author":"S Sano","year":"2018","unstructured":"Sano S, Kubo H, Morishima H, Goto R, Zheng R, Nakagawa H. Guselkumab, a human interleukin-23 monoclonal antibody in Japanese patients with generalized pustular psoriasis and erythrodermic psoriasis: efficacy and safety analyses of a 52-week, phase\u00a03, multicenter, open-label study. J Dermatol. 2018;45(5):529\u201339.","journal-title":"J Dermatol"},{"issue":"3","key":"1429_CR17","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1111\/bjd.14702","volume":"176","author":"K Yamasaki","year":"2017","unstructured":"Yamasaki K, Nakagawa H, Kubo Y, Ootaki K, Japanese Brodalumab Study Group. Efficacy and safety of brodalumab in patients with generalized pustular psoriasis and psoriatic erythroderma: results from a 52-week, open-label study. Br J Dermatol. 2017;176(3):741\u201351.","journal-title":"Br J Dermatol"},{"issue":"9","key":"1429_CR18","doi-asserted-by":"publisher","first-page":"2331","DOI":"10.1007\/s13555-024-01230-z","volume":"14","author":"L Puig","year":"2024","unstructured":"Puig L, Fujita H, Thaci D, et al. Current treatments for generalized pustular psoriasis: a narrative summary of a systematic literature search. Dermatol Ther (Heidelb). 2024;14(9):2331\u201378.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"2","key":"1429_CR19","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1007\/s13555-021-00493-0","volume":"11","author":"B Strober","year":"2021","unstructured":"Strober B, Kotowsky N, Medeiros R, et al. Unmet medical needs in the treatment and management of generalized pustular psoriasis flares: evidence from a survey of Corrona Registry dermatologists. Dermatol Ther (Heidelb). 2021;11(2):529\u201341.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"6","key":"1429_CR20","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1007\/s13555-021-00612-x","volume":"11","author":"A Menter","year":"2021","unstructured":"Menter A, Van Voorhees AS, Hsu S. Pustular psoriasis: a narrative review of recent developments in pathophysiology and therapeutic options. Dermatol Ther (Heidelb). 2021;11(6):1917\u201329.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"3","key":"1429_CR21","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1111\/1346-8138.17097","volume":"51","author":"Y Tada","year":"2024","unstructured":"Tada Y, Guan J, Iwasaki R, Morita A. Treatment patterns and drug survival for generalized pustular psoriasis: a patient journey study using a Japanese claims database. J Dermatol. 2024;51(3):391\u2013402.","journal-title":"J Dermatol"},{"issue":"1","key":"1429_CR22","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1111\/1346-8138.16217","volume":"49","author":"C Ohata","year":"2022","unstructured":"Ohata C, Tsuruta N, Yonekura K, et al. Clinical characteristics of Japanese pustular psoriasis: a multicenter observational study. J Dermatol. 2022;49(1):142\u201350.","journal-title":"J Dermatol"},{"issue":"10","key":"1429_CR23","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1080\/03007995.2021.1951192","volume":"37","author":"ML Hanna","year":"2021","unstructured":"Hanna ML, Singer D, Bender SD, Valdecantos WC, Wu JJ. Characteristics of hospitalizations and emergency department visits due to generalized pustular psoriasis in the United States. Curr Med Res Opin. 2021;37(10):1697\u2013703.","journal-title":"Curr Med Res Opin"},{"issue":"2","key":"1429_CR24","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1002\/jvc2.113","volume":"2","author":"A Morita","year":"2023","unstructured":"Morita A, Okubo Y, Imafuku S, et al. Assessment of flare frequency and severity of generalized pustular psoriasis in Japanese patients: a retrospective chart review study. JEADV Clin Pract. 2023;2(2):261\u201372.","journal-title":"JEADV Clin Pract"},{"issue":"3","key":"1429_CR25","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1080\/1744666X.2019.1708193","volume":"16","author":"S Kharawala","year":"2020","unstructured":"Kharawala S, Golembesky AK, Bohn RL, Esser D. The clinical, humanistic, and economic burden of generalized pustular psoriasis: a structured review. Expert Rev Clin Immunol. 2020;16(3):239\u201352.","journal-title":"Expert Rev Clin Immunol"},{"issue":"9","key":"1429_CR26","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1001\/archderm.1991.01680080075005","volume":"127","author":"BD Zelickson","year":"1991","unstructured":"Zelickson BD, Muller SA. Generalized pustular psoriasis. A review of 63 cases. Arch Dermatol. 1991;127(9):1339\u201345.","journal-title":"Arch Dermatol"},{"issue":"10","key":"1429_CR27","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1001\/jamadermatol.2022.3142","volume":"158","author":"CL Zema","year":"2022","unstructured":"Zema CL, Valdecantos WC, Weiss J, Krebs B, Menter AM. Understanding flares in patients with generalized pustular psoriasis documented in US electronic health records. JAMA Dermatol. 2022;158(10):1142\u20138.","journal-title":"JAMA Dermatol"},{"issue":"12","key":"1429_CR28","doi-asserted-by":"publisher","first-page":"2253","DOI":"10.1111\/jdv.15913","volume":"33","author":"L Eicher","year":"2019","unstructured":"Eicher L, Knop M, Aszodi N, Senner S, French LE, Wollenberg A. A systematic review of factors influencing treatment adherence in chronic inflammatory skin disease \u2014 strategies for optimizing treatment outcome. J Eur Acad Dermatol Venereol. 2019;33(12):2253\u201363.","journal-title":"J Eur Acad Dermatol Venereol"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01429-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-025-01429-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01429-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,31]],"date-time":"2025-05-31T09:59:25Z","timestamp":1748685565000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-025-01429-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,19]]},"references-count":28,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["1429"],"URL":"https:\/\/doi.org\/10.1007\/s13555-025-01429-8","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,19]]},"assertion":[{"value":"10 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Yukari Okubo declares receiving grants or contracts from Eisai, Maruho Pharmaceutical, and Torii Pharmaceutical, and consulting fees from AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Eisai, Eli Lilly, Janssen, JIMRO, Kyowa Kirin, LEO Pharma, Maruho Pharmaceutical, Mitsubishi Tanabe, Novartis, Pfizer, Sanofi, Sun Pharmaceutical Industries, Taiho Pharmaceutical, Torii Pharmaceutical, and UCB Japan. Ryuhei Okuyama declares receiving research grants, consulting fees, and\/or speaker fees from AbbVie, Amgen, Boehringer Ingelheim, Eisai, Eli Lilly, Janssen, Kyowa Kirin, LEO Pharma, Maruho Pharmaceutical, Mitsubishi Tanabe, Novartis, Pfizer, Sun Pharmaceutical Industries, Taiho Pharmaceutical, Torii Pharmaceutical, and UCB Japan. Shinichi Imafuku has served as a consultant for, paid speaker for, accepted a research grant from, and\/or participated in clinical trials sponsored by companies, including AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, Eisai, Eli Lilly, GSK, Janssen, Kyowa Kirin, LEO Pharma, Maruho Pharmaceutical, Meiji Seika, Novartis, Pfizer, Sun Pharmaceutical Industries, Taiho Pharmaceutical, Torii Pharmaceutical, Toyo Seiyaku Kasei, and UCB Japan. Yayoi Tada declares receiving honoraria and\/or grants from AbbVie, Boehringer Ingelheim, Eisai, Eli Lilly, Janssen, Kyowa Kirin, LEO Pharma, Maruho Pharmaceutical, Mitsubishi Tanabe, Novartis, Sun Pharmaceutical Industries, Taiho Pharmaceutical, Torii Pharmaceutical, and UCB Japan. Keiichi Yamanaka has served as a clinical trial investigator for AbbVie, Boehringer Ingelheim, Eli Lilly Japan, LEO Pharma, Janssen, Maruho Pharmaceutical, Merck Sharp & Dohme, Parexel, and UCB Japan; received research funding from AbbVie, Eisai, Eli Lilly Japan, Kyowa Kirin, Maruho Pharmaceutical, Sasaki Chemical, Sun Pharmaceutical Industries, Taiho Pharmaceutical, and Torii Pharmaceutical; and received speaker fees and Chair fees from AbbVie, Astellas Seiyaku, Boehringer Ingelheim, Celgene, Daiichi Sankyo, Eisai, Eli Lilly Japan, Janssen, Kyowa Kirin, LEO Pharma, Maruho Pharmaceutical, Mitsubishi Tanabe, Nippon Kayaku, Nippon Zoki, Novartis, Sato Seiyaku, Sanofi, Sun Pharmaceutical Industries, Taiho Pharmaceutical, and Torii Pharmaceutical. Kazumitsu Sugiura declares receiving research grants, consulting fees, and\/or speaker fees from AbbVie, Amgen, Bristol Myers Squibb, Eisai, Eli Lilly Japan, Janssen, Kyowa Kirin, LEO Pharma Japan, Maruho Pharmaceutical, Nippon Boehringer Ingelheim, Novartis, Taiho Pharmaceutical, Sun Pharmaceutical Industries, Torii Pharmaceutical, and UCB Japan. Yukie Yamaguchi declares receiving research grants, consulting fees, and\/or speaker fees from AbbVie, Amgen, Astellas, Boehringer Ingelheim, Bristol Myers Squibb, Eisai, Eli Lilly, Janssen, Kyowa Kirin, LEO Pharma, Maruho Pharmaceutical, Mitsubishi Tanabe, Novartis, Sun Pharmaceutical Industries, Taiho Pharmaceutical, Torii Pharmaceutical, and UCB Japan. Masahito Yasuda declares receiving consulting fees and\/or speaker fees from Boehringer Ingelheim, Janssen, Taiho Pharmaceutical, and Novartis, and participating in clinical trials sponsored by Eli Lilly. Wataru Sakamoto and Morihisa Saitoh are employees of Nippon Boehringer Ingelheim. Akimichi Morita declares receiving research grants, consulting fees, and\/or speaker fees from AbbVie, Boehringer Ingelheim, Eisai, Eli Lilly, Janssen, Kyowa Kirin, LEO Pharma, Maruho Pharmaceutical, Mitsubishi Tanabe, Nichi-Iko, Nippon Kayaku, Novartis, Sun Pharmaceutical Industries, Taiho Pharmaceutical, Torii Pharmaceutical, and Ushio.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The study protocol was approved by the ethics review committee of each institute as detailed in the supplementary information of the previous publication []. The study was performed in accordance with the Declaration of Helsinki. Written informed consent was obtained from patients (or their proxy if the patient was a minor or unable to provide informed consent) at a visit to the study site before registration of the patient on the electronic data capture system. Patients who were unlikely to visit the hospital because of transfer to a different hospital, or patients who had died, were registered for electronic data capture but were then opted out of follow-up. Instructions for opt-out were posted at the hospital or on its website.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}